Worldwide there are millions whose precious but failing eyesight could benefit from this discovery. It's hard to imagine the suffering that failing eyesight engenders until one gets older and experiences it first hand, or knows someone who is suffering from it.
"We hope this will lead to an affordable 'off-the-shelf' therapy that could be made available to NHS patients within the next five years."
"More than 600,000 people have age-related macular degeneration in the UK. It's the leading cause of blindness and the third globally."